Sorafenib (BAY 43-9006; Nexavar®, Bayer), an oral multi-kinases inhibitor targeting VEGFR, PDGFR and other kinases, represents first-line systemic therapy available for patients with advanced HCC and not eligible for tumor resection or liver transplantation. The gene discussed is KDR; the disease is hepatocellular carcinoma.